Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
NYSE:PBH
RESEARCH TOOLSreports
Holding PBH?
Track your performance easily
PBH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$56.34 - $75.80
Previous Close$73.55
Volume209.08K
Average Volume (3M)249.55K
Market Cap
$3.64B
Enterprise Value$4.71B
Total Cash (Recent Filing)$34.26M
Total Debt (Recent Filing)$1.10B
Price to Earnings (P/E)18.0
Beta0.42
Next Earnings
Oct 31, 2024EPS Estimate
$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.09
Shares Outstanding49,557,371
10 Day Avg. Volume201,336
30 Day Avg. Volume249,548
Standard Deviation0.07
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.17
Price to Sales (P/S)3.28
Price to Cash Flow (P/CF)16.80
P/FCF Ratio16.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.23
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda40.15
Forecast
1Y Price Target
$88.00Price Target Upside19.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Prestige Consumer Healthcare News
PremiumCompany Announcements
Prestige Consumer Healthcare Quarterly Financial Update
PremiumPre-Earnings
Is PBH a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformancePBH continues to generate a significant amount of cash due to low-to-mid-30s EBITDA margins with a niche portfolio of self-care products with limited risk of trading down or being restocked.
Market PositionPBH is a high-quality company with #1 or #2 brands in most of their categories, no cyclicality, and a 35% EBITDA margin.
Share Repurchase ProgramPBH just announced a $300M share repurchase program and indicated it was just 30% of the expected $1B in cash expected to be generated over the next 4 years, leaving plenty of allocation flexibility to M&A and brand investment.
Bears Say
Earnings4Q EPS misses on supply chain disruption, expect issues to be resolved by 2H, thesis remains intact.
SalesSales in 1H are still expected to be impacted by supply chain challenges from two eye-care suppliers as they both ramp up to speed.
Supply ChainPBH experienced significant disruptions in supply of Clear Eyes due to business interruptions from suppliers.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $56.34 and its highest was $75.80 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Currently, no data Available
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Aug 08, 2024. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.859 by $0.041.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare does not currently pay dividends.
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is $1.08.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 49,557,370 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $0.9 in its last earnings report, beating expectations of $0.859. Following the earnings report the stock price went down -1.547%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Among the largest hedge funds holding Prestige Consumer Healthcare’s share is Ariel Investments LLC. It holds Prestige Consumer Healthcare’s shares valued at 195M.
---
Prestige Consumer Healthcare Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.00 (19.68% Upside)
$88.00 (19.68% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 363.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.07%
12-Months-Change
Fundamentals
Return on Equity
12.98%
Trailing 12-Months
Asset Growth
-1.14%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
---
PBH Company Deck
---
PBH Earnings Call
Q1 2024
0:00 / 0:00
---
PBH Stock 12 Month Forecast
Average Price Target
$88.00
▲(19.68% Upside)
Technical Analysis
Best Analysts Covering PBH
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-6.45%
assigned a buy rating 23 days ago
Copying Linda Bolton Weiser's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -6.45% per trade.
---